TORONTO, Sept. 11, 2020 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the adoption of the Company’s amended and restated stock option plan and the Company’s amended and restated restricted share unit plan (together, the “Share Compensation Plans”). The Share Compensation Plans were approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020 (the “AGM”) and were previously approved by the Company’s board of directors and by the TSX Venture Exchange (“TSXV”), subject to shareholder approval at the AGM.
The board of directors may grant options and restricted share units (“RSUs”) under the Share Compensation Plans to attract, motivate and retain directors, officers, employees and consultants, and to align the interests of plan participants with those of the Company’s shareholders. The fixed number of shares issuable under the Share Compensation Plans and any other securities compensation arrangement (including the Company’s previous stock option and RSU plans) is 13,398,580, being 20% of the shares issued as at August 4, 2020, less the number of options and RSUs issued as at that date.
Following the approval by shareholders of the Share Compensation Plans, on September 10, 2020, the board of directors approved a grant of 1,210,000 RSUs to certain directors and officers of the Company under the amended and restated RSU plan, as set forth below. The RSUs will vest in thirds on each of the first, second and third anniversaries of the grant date.
| Name | Title/Position | Number of Shares |
| Chris Naprawa | Chairman | 400,000 |
| Deborah Rosati | Director | 400,000 |
| Alvaro Yanez | Director | 200,000 |
| Rayet Harb Gasi | Vice President, Khiron Health | 110,000 |
| Livia Maduri | General Counsel and Corporate Secretary | 100,000 |
| TOTAL | 1, 210,000 |
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, is fully authorized to manufacture and fill prescriptions for high- and low-THC medical cannabis in Colombia and has the first approved line of CBD cosmetic products on shelf in Colombia, and available in the United States and the United Kingdom.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Investor Contact: Paola Ricardo, E: pricardo@khiron.ca, T: +1 (786) 233-7411; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca; Khiron Europe: Tejinder Virk, Europe President, T: +44 (0) 7912 741 995, E: tvirk@khiron.ca
Get Real-Time Updates from MJobserver.com
